Ad4-mgag + Ad4-EnvC150

Ad4-mgag + Ad4-EnvC150 is a **combination of two live, replication-competent recombinant Adenovirus type 4 (Ad4) vector vaccines designed to prevent HIV infection**. Ad4-mgag encodes a mosaic HIV Gag antigen, while Ad4-EnvC150 encodes an HIV clade C Env protein (gp150 1086.C). Both vectors are formulated as enteric-coated capsules for oral administration or as aqueous formulations for tonsillar (intranasal) administration. The mechanism of action involves *inducing immune responses (cellular and humoral) against HIV Gag and Env proteins through delivery by replication-competent Ad4 vectors*. The primary indication is for **HIV prevention**. Development has been sponsored and led by **PaxVax** (now part of Emergent BioSolutions) and the National Institute of Allergy and Infectious Diseases (NIAID)[1][3][4].